Related Interviews

Midcap and Small-Cap Biopharma Opportunities a Better Way to Go in 2021
September 30, 2020
Singh, Hartaj

Innovation Continues to Be Strong Despite Volatility in Biotech Sector
March 20, 2020
Zhong, Yun

Several Readouts on Allogeneic Cell Therapy Expected in 2020
March 20, 2020
Prasad, Raju

M&A Starting to Pick Up as Valuations Come Down
October 04, 2019
Yang, Difei

Major Pharmas Becoming Increasingly Comfortable with Gene Therapy
March 22, 2019
Zhong, Yun

Clinical Data and M&A Serve as Catalysts in 2019
March 22, 2019
Roy, Soumit

International Markets Offering Low Valuations and Faster Pace of Growth
July 27, 2018
Kornitzer, Bill

Managing an International High Dividend Yield Strategy
June 01, 2018
Buchwald, Richard E., Kline, Marvin I.

Good Management Teams and Good Science are Creating Opportunities in Biotech
March 08, 2018
Singh, Hartaj

Finding Higher-Quality Names in Animal Health, Diagnostics and Life Science Tools
November 03, 2017
Westenberg, David

Life Science Growth Likely to Moderate in 2017
April 21, 2017
Morozov, Alex

Drug Pricing Power Moves from Pharmaceutical Companies to Pharmacy Benefit Managers
March 10, 2017
McGarry, Stephen

A Cautious Perspective on the Biotechnology Sector
March 10, 2017
Shrader, Thomas

Strong Incentives for M&A Activity in the Biotechnology Sector
March 10, 2017
Olson, Jay

Seeking Global Equities with High Returns on Invested Capital
September 23, 2016
Perez Fernandez, Francisco Javier

Looking for Biopharmaceuticals with Disruptive Innovation and Medicines Initiatives
August 12, 2016
Amusa, Gbola

Stronger Growth Expected for Life Science Tools and Diagnostics
March 11, 2016
Brokmeier, Bryan